Shares of Nevro Corp. (NYSE:NVRO) have received a consensus rating of “Hold” from the ten research firms that are currently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $102.00.

Several research firms have weighed in on NVRO. Northland Securities restated a “buy” rating and set a $96.00 price objective on shares of Nevro Corp. in a report on Tuesday, August 8th. BMO Capital Markets restated a “buy” rating and set a $106.00 price objective on shares of Nevro Corp. in a report on Friday, September 1st. Morgan Stanley upped their price objective on shares of Nevro Corp. from $87.00 to $95.00 and gave the stock an “overweight” rating in a report on Tuesday, August 8th. J P Morgan Chase & Co restated an “overweight” rating and set a $102.00 price objective on shares of Nevro Corp. in a report on Monday, July 3rd. Finally, Zacks Investment Research downgraded shares of Nevro Corp. from a “hold” rating to a “sell” rating in a report on Saturday, June 3rd.

In related news, CFO Andrew H. Galligan sold 7,000 shares of the stock in a transaction dated Monday, August 14th. The shares were sold at an average price of $82.31, for a total transaction of $576,170.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Michael F. Demane sold 5,000 shares of the stock in a transaction dated Wednesday, September 13th. The shares were sold at an average price of $89.50, for a total transaction of $447,500.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 264,440 shares of company stock valued at $22,259,907. 12.10% of the stock is owned by company insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Dynamic Technology Lab Private Ltd grew its position in Nevro Corp. by 8.9% during the second quarter. Dynamic Technology Lab Private Ltd now owns 6,857 shares of the medical equipment provider’s stock valued at $510,000 after buying an additional 559 shares during the period. Asymmetry Capital Management L.P. grew its position in Nevro Corp. by 122.9% during the second quarter. Asymmetry Capital Management L.P. now owns 60,893 shares of the medical equipment provider’s stock valued at $4,532,000 after buying an additional 33,575 shares during the period. Sterling Capital Management LLC bought a new position in Nevro Corp. during the second quarter valued at about $233,000. Ameritas Investment Partners Inc. boosted its position in Nevro Corp. by 17.3% during the second quarter. Ameritas Investment Partners Inc. now owns 2,432 shares of the medical equipment provider’s stock worth $181,000 after purchasing an additional 358 shares during the period. Finally, California State Teachers Retirement System boosted its position in Nevro Corp. by 3.6% during the second quarter. California State Teachers Retirement System now owns 49,063 shares of the medical equipment provider’s stock worth $3,652,000 after purchasing an additional 1,689 shares during the period.

ILLEGAL ACTIVITY WARNING: “Nevro Corp. (NVRO) Given Consensus Rating of “Hold” by Brokerages” was reported by American Banking News and is the property of of American Banking News. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international copyright law. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/09/16/nevro-corp-nvro-given-consensus-rating-of-hold-by-brokerages.html.

Nevro Corp. (NYSE:NVRO) opened at 87.88 on Friday. Nevro Corp. has a 52-week low of $65.82 and a 52-week high of $106.93. The company’s market cap is $2.59 billion. The company has a 50-day moving average of $85.38 and a 200-day moving average of $84.23.

Nevro Corp. (NYSE:NVRO) last released its quarterly earnings data on Monday, August 7th. The medical equipment provider reported ($0.40) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.29) by ($0.11). Nevro Corp. had a negative return on equity of 16.25% and a negative net margin of 14.33%. The business had revenue of $78.02 million for the quarter, compared to analyst estimates of $77.75 million. During the same quarter in the previous year, the company posted ($0.31) EPS. The business’s quarterly revenue was up 40.8% on a year-over-year basis. On average, equities research analysts expect that Nevro Corp. will post ($1.16) earnings per share for the current fiscal year.

About Nevro Corp.

Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.

Analyst Recommendations for Nevro Corp. (NYSE:NVRO)

Receive News & Ratings for Nevro Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro Corp. and related companies with MarketBeat.com's FREE daily email newsletter.